Duchenne patients recruited for steroid replacement study

We are delighted to announce that ReveraGen BioPharma, the company developing a steroid replacement for Duchenne muscular dystrophy, has begun recruiting patients for its Phase 2a open label study. The trial will be recruiting patients who haven’t yet started...
Ten posts in place to support UK clinical trial capacity

Ten posts in place to support UK clinical trial capacity

In December 2015, eight patient organisations, who are working to help support clinical trial development for Duchenne muscular dystrophy, announced a total of £1.2million of investment, to fund a total of 16 clinical posts. Today we are announcing that TEN of those...
DRF raises £1.2 million to help beat Duchenne

DRF raises £1.2 million to help beat Duchenne

The Duchenne Research Fund raised £1.2 million at its ‘The Time Is Now’ Gala Dinner on 5 May at the Lancaster London Hotel to help find a cure for Duchenne muscular dystrophy – the biggest genetic killer of children worldwide. The funds raised will enable the DRF to...

DRF-funded drug development programme receives further £4.6 million

The Duchenne Research Fund, the Duchenne Children’s Trust and Joining Jack and are delighted with the news from the John Walton Muscular Dystrophy Research Centre that they have received £4.6 million in European funding for a Phase II clinical trial for Vamorolone –...
Dog with dystrophin mutation saved from Duchenne

Dog with dystrophin mutation saved from Duchenne

DRF-funded research was published this week in Cell, one of the world’s most prestigious scientific journals, analysing why two golden retrievers showed no severe symptoms of Duchenne muscular dystrophy and unexpectedly lived a normal lifespan despite being born...
DRF’s funding of Solid GT leads to $42.5 million investment

DRF’s funding of Solid GT leads to $42.5 million investment

We are thrilled that the money raised through the Duchenne Research Fund’s 2013 dinner and donations since then have enabled us to seed fund the incredible Solid GT project, which has today received industry investment (read the press release below). While gene...
Albourne raises £155,000 for DRF

Albourne raises £155,000 for DRF

We are immensely grateful to Albourne Partners and their supporters for raising more than £155,000 for our projects at their incredible performance of ‘The Importance of Being Lewis’ on 7 October. The event was held to honour the memory of Jacques Joubert...

Gene therapy breakthrough in muscular dystrophy dogs

The Duchenne Research Fund is incredibly proud of Dr Dongsheng Duan – an important Scientific Advisory Board member of Solid GT, a gene therapy programme pioneered by Solid Biosciences and that we helped to fund. Dr Duan’s latest gene therapy work on...

DRF-funded study shows encouraging results in combating muscle-wasting

Professor Dame Kay Davies (University of Oxford) and her group have recently published encouraging results of a study to test new second-generation compounds to increase the level of utrophin protein as a treatment for boys and men with Duchenne and Becker muscular...